These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Neurotransmitters and CNS disease. Schizophrenia. Snyder SH Lancet; 1982 Oct; 2(8305):970-4. PubMed ID: 6127468 [No Abstract] [Full Text] [Related]
45. Serotonergic modulation of dopamine neurotransmission: a mechanism for enhancing therapeutics in schizophrenia. Haleem DJ J Coll Physicians Surg Pak; 2006 Aug; 16(8):556-62. PubMed ID: 16899192 [TBL] [Abstract][Full Text] [Related]
46. Choosing among old and new antipsychotics. J Clin Psychiatry; 1996 Sep; 57(9):427-38. PubMed ID: 9746456 [No Abstract] [Full Text] [Related]
47. Clinical and neuroendocrine studies with cholecystokinin peptides. Nair NP; Bloom D; Lal S; Debonnel G; Schwartz G; Mosticyan S Ann N Y Acad Sci; 1985; 448():535-41. PubMed ID: 2862831 [No Abstract] [Full Text] [Related]
48. Associations among plasma prolactin levels, tardive dyskinesia, and paranoia in treated schizophrenics: relevance to supersensitivity psychosis. Csernansky JG; Vinogradov S; Prosser E; Kaplan J; Berger PA; Hollister LE Psychopharmacol Bull; 1986; 22(3):897-9. PubMed ID: 2879311 [No Abstract] [Full Text] [Related]
49. Amisulpride: a review of its use in the management of schizophrenia. Curran MP; Perry CM Drugs; 2001; 61(14):2123-50. PubMed ID: 11735643 [TBL] [Abstract][Full Text] [Related]
50. Pharmacotherapy of schizophrenia: a review. Sigmundson HK Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S70-5. PubMed ID: 7533053 [TBL] [Abstract][Full Text] [Related]
51. Dopamine and the pathophysiology of dyskinesias induced by antipsychotic drugs. Baldessarini RJ; Tarsy D Annu Rev Neurosci; 1980; 3():23-41. PubMed ID: 6106450 [No Abstract] [Full Text] [Related]
53. Maintenance therapy and the natural course of schizophrenia. Davis JM J Clin Psychiatry; 1985 Nov; 46(11 Pt 2):18-21. PubMed ID: 2865252 [TBL] [Abstract][Full Text] [Related]
54. Receptor mechanisms in antipsychotic drug action: focus on sigma receptors. Snyder SH; Largent BL J Neuropsychiatry Clin Neurosci; 1989; 1(1):7-15. PubMed ID: 2577720 [TBL] [Abstract][Full Text] [Related]
55. The possible role of dopamine autoreceptors in neuroleptic atypicality. Javitt DC; Weinstein SL; Opler LA Psychiatr Dev; 1988; 6(1):57-71. PubMed ID: 2902622 [TBL] [Abstract][Full Text] [Related]
56. [Neuroleptics and dopamine. How the antipsychotic breakthrough resulted in improved knowledge about the biology of schizophrenia]. Fog R Ugeskr Laeger; 2000 Jan; 162(1):68-9. PubMed ID: 10658506 [No Abstract] [Full Text] [Related]
57. Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Strange PG Pharmacol Rev; 2001 Mar; 53(1):119-33. PubMed ID: 11171942 [TBL] [Abstract][Full Text] [Related]
58. Down-regulation of central dopamine receptors in schizophrenia. Zemlan FP; Hitzemann RJ; Hirschowitz J; Garver DL Am J Psychiatry; 1985 Nov; 142(11):1334-7. PubMed ID: 2865903 [TBL] [Abstract][Full Text] [Related]
59. The emerging role of atypical antipsychotics in the treatment of tardive dyskinesia induced by other atypical antipsychotics. Peritogiannis V; Tsouli S J Clin Psychiatry; 2011 Jul; 72(7):1016; author reply 1016-7. PubMed ID: 21824463 [No Abstract] [Full Text] [Related]
60. [Current concepts of the effects of neuroleptics]. Kostowski W; Płaźnik A Psychiatr Pol; 1990; 24(5):28-37. PubMed ID: 1983397 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]